Free tool
FAERS Monitor: Rifadin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050627 or its brand name (Rifadin, Rifampin). Reports on generic versions are filed under their own applications.
Reports
10,069
Serious
9,802
97% of reports
Hospitalization
4,801
Death reported
1,594
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction1,008
- pyrexia919
- drug reaction with eosinophilia and systemic symptoms558
- drug ineffective518
- vomiting452
- drug-induced liver injury442
- nausea394
- acute kidney injury362
- jaundice360
- condition aggravated347
- thrombocytopenia310
- rash302
- paradoxical drug reaction295
- eosinophilia287
- drug resistance268
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 214 |
| 2005 | 242 |
| 2006 | 308 |
| 2007 | 255 |
| 2008 | 316 |
| 2009 | 337 |
| 2010 | 337 |
| 2011 | 331 |
| 2012 | 516 |
| 2013 | 558 |
| 2014 | 555 |
| 2015 | 676 |
| 2016 | 721 |
| 2017 | 917 |
| 2018 | 1,082 |
| 2019 | 1,023 |
| 2020 | 929 |
| 2021 | 610 |
| 2022 | 33 |
| 2023 | 34 |
| 2024 | 23 |
| 2025 | 28 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,090 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paradoxical drug reactionSignal | 295 | 182.0 | 161.8 | 48,685 |
| drug reaction with eosinophilia and systemic symptomsSignal | 558 | 46.3 | 42.7 | 24,170 |
| eosinophiliaSignal | 287 | 34.8 | 31.0 | 9,233 |
| drug-induced liver injurySignal | 442 | 29.8 | 27.2 | 12,133 |
| jaundiceSignal | 360 | 28.3 | 25.6 | 9,346 |
| drug resistanceSignal | 268 | 22.0 | 19.5 | 5,305 |
| drug interactionSignal | 1,008 | 13.4 | 12.6 | 11,519 |
| thrombocytopeniaSignal | 310 | 5.8 | 5.2 | 1,231 |
| pyrexiaSignal | 919 | 5.6 | 5.2 | 3,481 |
| acute kidney injurySignal | 362 | 5.0 | 4.5 | 1,143 |
| condition aggravatedSignal | 347 | 2.4 | 2.2 | 282 |
| vomitingSignal | 452 | 2.0 | 1.8 | 233 |
| rash | 302 | 1.4 | 1.3 | 42 |
| nausea | 394 | 1.0 | 0.9 | 1 |
| drug ineffective | 518 | 0.8 | 0.8 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.